Get Ready for a Revolution in Weight Management: 2026 Could Mark the Arrival of Oral Obesity Medications from Novo Nordisk and Eli Lilly!
The landscape of obesity treatments is on the brink of a significant transformation, with promising oral GLP-1 medications poised to enter the market. These innovative drugs are expected to provide a more accessible and possibly more affordable option compared to the current popular injectable treatments.
Novo Nordisk and Eli Lilly are leading the charge with their daily oral weight loss pills, which may attract a broader range of patients. This includes those who have a fear of needles or individuals who might benefit from these medications but do not feel that their weight management needs are critical enough to warrant injections.
While these upcoming pills might not surpass the effectiveness of existing weekly injections, experts emphasize that broadening treatment choices can be a game-changer for many. After experiencing supply shortages of their injectable products recently, both companies are taking proactive steps to ensure they can adequately supply the anticipated demand for their new pills.
According to a report from Goldman Sachs in August, analysts predict that oral medications could secure a notable 24% market share—approximately $22 billion—of the global weight loss drug market by 2030, which they estimate will reach a total value of $95 billion.
Key Details About the New Pills
Timing of Launch
In a competitive race, Novo Nordisk appears likely to hit the market first. The company’s oral semaglutide—an active component in its injection products Wegovy and Mounjaro—is expected to gain approval before the year concludes. This positions it well for an early launch in 2026 under the Wegovy brand as a pill.
On the other hand, Eli Lilly has yet to submit its application for the oral GLP-1 known as orforglipron, but plans to do so by year-end. Notably, the FDA has awarded priority review status to this medication, which could accelerate its approval process, allowing it to enter the market within the same timeframe as its competitor.
Cost Considerations
At this time, neither company has disclosed specific pricing details for their forthcoming pills. However, both firms have indicated plans to offer discounts to consumers. Under recent agreements made during Donald Trump’s presidency, starting doses of these pills are expected to cost $149 per month for patients ordering through the direct-to-consumer platform, TrumpRx, set to debut in January. This pricing strategy is already lower than the discounted rates for the companies’ current injectable treatments, which typically list around $1,000 per month before insurance coverage kicks in.
Effectiveness and Market Rivalry
Directly comparing the results from the separate clinical trials of both medications poses challenges due to different trial designs and participant sizes. For instance, Eli Lilly conducted its ATTAIN-1 trial with around 3,000 participants, while Novo Nordisk's OASIS 4 study included only about 300 individuals. Currently, there are no studies that directly pit one treatment against the other.
However, some analysts suggest that Novo Nordisk’s oral semaglutide may lead to greater weight loss compared to Eli Lilly’s alternative based on the data available. In Eli Lilly’s study, the highest dose resulted in an average weight loss of 12.4% over 72 weeks, and 11.2% when considering all participants, including those who stopped taking the drug.
Conversely, Novo Nordisk’s 25-milligram dosage was associated with an impressive average weight reduction of 16.6% over 64 weeks, with a general loss of 13.6% when accounting for all participants regardless of discontinuation.
Despite the potential for slightly lesser efficacy in Eli Lilly’s formulation, experts from Goldman Sachs anticipate that it will capture approximately 60% of the daily oral market segment—around $13.6 billion—by 2030. In contrast, they predict Novo Nordisk’s oral semaglutide will hold about 21% of that market, equating to roughly $4 billion, while the remaining share will be absorbed by other emerging products.
Looking ahead, several other pharmaceutical companies, including Viking Therapeutics, Structure Therapeutics, AstraZeneca, Roche, and Pfizer, are currently developing their own obesity medications, which means we can expect even more data on these innovative therapies in the coming year.
Stay tuned for further updates on this exciting development in weight management! If you have insights or opinions on this topic, feel free to share your thoughts in the comments below. Are you excited about the potential of oral obesity medications, or do you have concerns? Let’s discuss!
